BioStock: Major acquisition to strengthen Merck's immunology pipeline

It was recently announced that Merck is acquiring Prometheus Biosciences for approximately 10.8 billion USD. The acquisition gives Merck an entry point into the immunology market and will also protect the company from the loss of revenue expected when the patent for the cancer drug Keytruda expires in 2028. At the end of last year, Prometheus presented positive results for its drug candidate PRA023, which prompted Merck to make the acquisition decision.

Read the full article about Merck's acquisition at biostock.se:

https://www.biostock.se/en/2023/04/major-acquisition-to-strengthen-mercks-immunology-pipeline/

This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/en/